Marolleau, Jean-Pierre

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

Raffoux, E., Cras, A., Recher, C., Boëlle, P.-Y., de Labarthe, A., Turlure, P., Marolleau, J.-P., Reman, O., Gardin, C., Victor, M., et al. (2010) · Oncotarget

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 134

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML:GFM's “pick a winner” trial, with the impact of somatic mutations

Adès, L., Duployez, N., Guerci‐Bresler, A., Laribi, K., Peterlin, P., Vey, N., Thepot, S., Wickenhauser, S., Zerazhi, H., Stamatoullas, A., et al. (2022) · British Journal of Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 21